Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06060080 | Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma | unknown | N/A | 7 | Yao LiuOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03490084 |
| Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma(PAMM-HAD1) |
| unknown |
| — |
| 300 |
| Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Aug 28, 2023 |
| clinicaltrials |
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | unknown | Phase 1 / Phase 2 | 73 | Sara V. LatorreOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT06007989 | Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)(CHIME) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05995808 | Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests | unknown | N/A | 30 | Sohag UniversityOTHER | 0 | Aug 16, 2023 | clinicaltrials |
| NCT05005299 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) | unknown | Phase 1 | 18 | Melbourne HealthOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05964270 | Telemonitoring Among Patients With Multiple Myeloma(ITUMM) | unknown | N/A | 150 | IsalaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04143932 | Multiple Myeloma Turkish Prospective Patient Registry(THD-MM-Reg) | unknown | — | 1,000 | Turkish Hematology AssociationOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04836871 | Double Filtration Plasmapheresis Combined With Chemotherapy | unknown | Phase 1 | 20 | Fuling ZhouOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04814615 | A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | unknown | Phase 2 | 60 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05920876 | A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma | unknown | Phase 1 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT03809780 | Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone(LENDER) | unknown | Phase 2 | 70 | Kosin University Gospel HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03641456 | VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03090659 | LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma(LEGEND-2) | unknown | Phase 1 / Phase 2 | 100 | Nanjing Legend Biotech Co.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05893693 | Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 12 | Aibin Liang，MD，Ph.D.OTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05860179 | Examination of Trends in Multiple Myeloma Trial Patient Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 23, 2023 | clinicaltrials |
| NCT05271682 | A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma | unknown | Phase 1 | 40 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05858203 | Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment(AATF/Che-1) | unknown | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05749133 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | XuYanOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05822037 | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 6 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04861480 | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05438394 | Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM | unknown | Phase 1 | 24 | Peking University People's HospitalOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05308225 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 72 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05802992 | The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | unknown | Phase 3 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | unknown | — | 150 | Maastricht University Medical CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 48 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04941937 | Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM | unknown | Phase 2 | 90 | Juan DuOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05739188 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05740891 | AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma | unknown | Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05712083 | A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma | unknown | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04309084 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | unknown | Phase 1 | 29 | Celularity IncorporatedINDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05718401 | The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics | unknown | — | 500 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04706936 | Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05432414 | PVd Versus Vd in NDMM Patients With RI | unknown | Phase 2 | 79 | RenJi HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05698303 | A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05693012 | Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma | unknown | — | 398 | Qiu LuguiOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05007418 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 54 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT04287855 | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 82 | Poitiers University HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619861 | CAR-T Cells in the Treatment of Malignant Hematological Tumors | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05577884 | Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma | unknown | — | 30 | Seoul National University HospitalOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 29, 2023source: clinicaltrials